demonstrated the safety and efficacy of ex vivo expanded ILC2s (Ex ILC2s) in AML models, showing tumor cell killing through GzmB without inducing cytokine release syndrome or neurotoxicity (218). The gene discussed is GZMB; the disease is neoplasm.